Many different types of cancer originate from aberrant signaling from the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (RTK), arising through different translocation events and overexpression. Further, activating point mutations in the ALK domain have been recently reported in neuroblastoma. To characterize signaling in the context of the full-length receptor, we have examined whether ALK is able to activate Rap1 and contribute to differentiation/proliferation processes. We show that ALK activates Rap1 via the Rap1-specific guaninenucleotide exchange factor C3G, which binds in a constitutive complex with CrkL to activated ALK. The activation of the C3G/Rap1 pathway results in neurite outgrowth of PC12 cells, which is inhibited by either overexpression of Rap1GAP or siRNA-mediated knockdown of Rap1 itself or the guanine nucleotide exchange factor C3G. Significantly, this pathway also appears to function in the regulation of proliferation of neuroblastoma cells such as SK-N-SH and SH-SY5Y, because abrogation of Rap1 activity by Rap1-specific siRNA or overexpression of Rap1GAP reduces cellular growth. These results suggest that ALK activation of Rap1 may contribute to cell proliferation and oncogenesis of neuroblastoma driven by gain-of-function mutant ALK receptors.
Introduction
Anaplastic lymphoma kinase (ALK) belongs to the insulin receptor superfamily of receptor tyrosine kinases (RTKs) (Iwahara et al., 1997; Morris et al., 1997) , and was initially characterized as one of the fusion partners in the nucleophosmin (NPM)-ALK oncogene found in a subset of anaplastic large cell lymphomas. NPM-ALK is the result of a chromosomal translocation event that places the C-terminal portion of ALK together with the N-terminal part of NPM (Morris et al., 1994; Shiota et al., 1994 Shiota et al., , 1995 . A variety of ALK fusion proteins have since been described in inflammatory myofibroblastic tumors, non-small cell lung cancer, diffuse B-cell lymphomas and squamous cell carcinoma of the esophagus (reviewed by Palmer et al., 2009) . Together with the reported expression of ALK in a number of cell lines and tumors, these findings suggest a function for inappropriately activated ALK in oncogenic progression (reviewed by Palmer et al., 2009) . Neuroblastoma, which is derived from neural crest cells and can occur in the entire peripheral sympathetic nervous system, accounts for approximately 15% of all pediatric cancer deaths (Maris et al., 2007) . Amplification of the ALK locus has been observed in neuroblastoma cell lines as well as patient samples (Lamant et al., 2000; Miyake et al., 2002; Osajima-Hakomori et al., 2005) and recent studies have reported activating ALK point mutations in both familial and sporadic cases of neuroblastoma, in addition to a number of neuroblastoma cell lines (Caren et al., 2008; Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008) . Taken together, aberrant ALK activation appears to be involved in tumor progression in a growing number of tumor types, consequently making the understanding of signaling emanating from this RTK an important aim. Although many studies have addressed the mechanisms of action used by oncogenic ALK fusion proteins (primarily NPM-ALK), the physiological functions of ALK and its downstream targets in mouse and humans are far from clear. In mammals, ALK has been suggested to be involved in the normal development and function of the nervous system (Iwahara et al., 1997; Morris et al., 1997; Vernersson et al., 2006; Bilsland et al., 2008) . However, the reported presence of differently sized ALK mRNA, suggests that differential splicing and additional functions of ALK may exist (Morris et al., 1994) .
Studies of ALK-like RTKs in other species have expanded the knowledge of ALK in normal physiology. In Drosophila melanogaster ALK has a major function in the development of the visceral musculature of the midgut in vivo (Loren et al., 2001 Lee et al., 2003; Stute et al., 2004) , a process during which Jelly belly (Jeb) ligand-mediated activation of ALK forces the extracellular signal-regulated kinase (ERK)/mitogenactivated protein kinase (MAPK) pathway to induce muscle cell specification Lee et al., 2003; Stute et al., 2004) . In agreement, the Caenorhabditis elegans Jeb homologue Hen-1 was recently identified as a ligand for SCD-2, the homologue of mammalian ALK (Ishihara et al., 2002; Liao et al., 2004; Reiner et al., 2008) . In both these species, ALK has furthermore been shown to be important for neuronal functions. In the fruit fly ALK and Jeb are required for neuronal circuit assembly in the visual system, mediating correct targeting of photoreceptor axons (Bazigou et al., 2007) , whereas ALK in C. elegans is expressed in motor neurons, where it is involved in the neuronal control of entry into dauer as well as synapse stabilization (Liao et al., 2004; Reiner et al., 2008) . Furthermore, in the zebrafish model system it has been shown that LTK, which belongs to the LTK/ALK family, is expressed in developing neural crest cells and is important for the specification of iridophores from the neural crest linage (Lopes et al., 2008) .
To date, there are no reports of Jeb-like ligands for mammalian ALK. Instead, the small heparin binding peptide ligands, midkine and pleiotrophin, have been described as activating ligands for vertebrate ALK. However, the functional significance of this ligand/ receptor interaction in vivo is not fully understood (Stoica et al., 2001 (Stoica et al., , 2002 Muramatsu, 2002) .
In the mouse, ALK is strongly expressed in the nervous system during embryogenesis, suggesting a function for mammalian ALK in this tissue. Supporting this hypothesis, in vitro studies have shown that ALK induces neuronal differentiation of PC12 and SK-N-SH cells in a MAPK-dependent manner Motegi et al., 2004; Gouzi et al., 2005; Moog-Lutz et al., 2005; Yang et al., 2007) . Moreover, a recent study of ALK knockout mice has implicated a function for ALK in the adult brain, where it appears to regulate the function of the frontal cortex and hippocampus, and may be involved in dopaminergic signaling (Bilsland et al., 2008) .
Rap1 is a small GTPase involved in the regulation of cell adhesion, polarity, secretion and cell-cell junction formation, processes in which it is controlled by an extensive set of activating guanine nucleotide exchange factors (GEFs) and inhibitory GTPase-activating proteins (GAPs) (Raaijmakers and Bos, 2009 ). Interestingly, Rap1 appears to have a function in neurite outgrowth and neuronal polarization by mediating sustained MAPK pathway activation in addition to regulating the cytoskeleton (York et al., 1998; Kao et al., 2001; Wu et al., 2001; Schwamborn and Puschel, 2004) . Further, Rap1 is also involved in the regulation of cell proliferation. When overexpressed, Rap1 induces oncogenic transformation in Swiss-3T3 cells (Altschuler and Ribeiro-Neto, 1998) , and has been reported to be activated in metastatic mammary carcinomas, during melanoma tumorigenesis as well as metastasis (Hemmeryckx et al., 2001; Gao et al., 2006) . Rap1 also appears to be involved in the process of thyroid mitogenesis and has been suggested to contribute to thyroid-stimulating hormone-stimulated thyroid tumorigenesis Hong et al., 2008) . However, in contrast to these findings, Rap1 has been shown in other studies to suppress oncogenesis (Lin et al., 2000) . To date a function for Rap1 in the development of neuroblastoma has not been investigated.
Rap1 is activated by GEFs such as C3G, the Epac family proteins, CD-GEFs and PDZ-GEFs (reviewed by Bos et al., 2001) . Interestingly, during mouse embryogenesis, C3G has essential functions in vascular maturation and the development of the nervous system (Voss et al., 2003 (Voss et al., , 2006 (Voss et al., , 2008 . Further, small-interfering RNAs (siRNA)-mediated knockdown of C3G results in decreased neurite outgrowth in PC12 cells and C3G has been suggested to regulate differentiation and survival of human neuroblastoma cells (Hisata et al., 2007; Radha et al., 2008) . Besides C3G, the atypical RapGEF DOCK4, which displays dual activity toward both Rap1 and Rac, also appears to exhibit oncogenic capacity (Yajnik et al., 2003) .
Due to its very low intrinsic GTPase activity, inactivation of Rap1 relies on GTP hydrolysis by GAPs, including Rap1GAP and members of the Spa1 family (reviewed by Bos et al., 2001) . Importantly, tuberin, a product of a familial tuberous sclerosis gene, that also displays in vitro Rap1GAP activity, induces benign tumors when deleted (Wienecke et al., 1995) . Enhanced Rap1 activity due to decreased Rap1GAP expression has been recently reported in prostate cancer cell lines, leading to increased cell migration and invasive behavior (Bailey et al., 2009) . Thus, deregulated Rap1 signaling is implicated in the pathogenesis of a variety of malignancy types, including leukemia, neuroblastoma and prostate cancer (reviewed by Minato and Hattori, 2009 ).
Here we observe that stimulation of mALK triggers activation of Rap1 and that this activity is indeed important for efficient ALK-mediated neurite outgrowth in PC12 cells. In part, ALK-induced Rap1 activation appears to be mediated by C3G, which in complex with CrkL is recruited to the activated mALK receptor. Furthermore, we have observed that the activation of Rap1 by ALK contributes to cell growth and tumorigenesis of the neuroblastoma cell lines SK-N-SH and SH-SY5Y, emphasizing a significant function of Rap1 in ALK-induced cell transformation.
Results

Rap1 is activated in response to ALK stimulation
We wished to investigate whether mouse ALK is able to activate Rap1. To do this, we used a PC12 cell system in which expression of ALK can be induced by tetracycline, together with an agonist monoclonal antibody (mAb46) that has been previously reported to bind and activate mALK in vivo (Yang et al., 2007) . Indeed, activation of mALK with mAb46 resulted in an extensive Rap1 activation, as shown by pull down with GST-RalGDS (Figure 1 ). Active Rap1 (that is, GTP bound) could be detected as early as 5 min after stimulation, was sustained for at least 60 min and decreased only after 120 min. Interestingly, the pattern of Rap1 activation is highly similar to that of ERK phosphorylation and activation, which was monitored as a control for ALK activation.
Rap1 knockdown inhibits ALK-stimulated neurite outgrowth Next we wanted to investigate whether Rap1 is involved in ALK-mediated stimulation of neurite outgrowth. Differentiation and consequently neurite outgrowth of PC12 cells can be efficiently achieved by stimulating mALK with mAb46 (Yang et al., 2007) . To experimentally clarify a putative function for Rap1 in ALKinduced neurite outgrowth, we first used RNA interference (RNAi) to knockdown Rap1 expression in PC12 cells. Importantly, the reduction of Rap1 protein levels in PC12 cells was substantial and independent of mALK expression status (Figure 2a , compare lane 4 with 3). When knocking down Rap1, we observed a distinct decrease in nerve growth factor (NGF)-induced neurite outgrowth of approximately 50% as compared to nontreated PC12 cells (Figure 2b ). Moreover, this result was confirmed with a second independent siRNA targeting Rap1 (Supplementary Figure 2) . Similar results were also obtained in mALK-expressing PC12 cells on stimulation with mAb46, in which transfection of siRNA against Rap1 caused a 40% reduction of neurite outgrowth as compared with control cells.
Rap1GAP expression blocks mAb46-induced neurite outgrowth in mALK-expressing PC12 cells In a second approach to block Rap1 activity in the cell, PC12 cells were transfected with a plasmid encoding the Rap1-specific GAP Rap1GAP (HA-Rap1GAP), which is known to abrogate Rap1 activity. Subsequent to transfection of mALK-expressing PC12 cells with HA-tagged Rap1GAP, we monitored mAb46-induced neurite outgrowth. In agreement with previous results, inhibition of Rap1 activity by Rap1GAP overexpression caused a dramatic reduction of NGFinduced neurite outgrowth in mALK-nonexpressing PC12 cells (Figures 3a and b) . Similarly, mAb46-induced neurite outgrowth in mALK-expressing PC12 cells was also robustly inhibited by the presence of HARap1GAP (Figures 3a and b ).
Rap1 GEF C3G is activated on stimulation of mALK The Rap1-specific GEF C3G is expressed in PC12 cells and has been reported to have a function in neurite outgrowth (York et al., 1998; Kao et al., 2001) . We therefore investigated whether activation of mALK had any effect on C3G activation. Initially, we performed immunoprecipitation experiments to examine whether C3G is recruited to mALK in response to receptor stimulation. As previously reported, a constitutive interaction between C3G and CrkL could be clearly detected by immunoprecipitation with antibodies against either C3G or CrkL, independent of mALK stimulation (Figures 4a and b) (Feller et al., 1995) . On stimulation with mAb46, we could observe tyrosine phosphorylation of mALK, indicating successful activation of the receptor (Figure 4a ). Activation of mALK-induced signaling was moreover confirmed by phosphorylation of ERK in cell lysates as a result of stimulation by the ligand mAb46. In addition, after mAb46 stimulation, we found mALK protein to be present in coimmunoprecipitates, using either anti-C3G or anti-CrkL antibodies, indicating the formation of a multiprotein complex comprising C3G, CrkL and mALK (Figures 4a and b) . Taken together, these results suggest that activated mALK recruits the constitutive C3G/CrkL complex to the site of receptor stimulation.
To further address the mechanism of activation of C3G, we analyzed the tyrosine-phosphorylation status of C3G in response to mALK stimulation. To do this, we used commercially available beads coupled to antiphosphotyrosine antibodies (4G10) to immunoprecipitate proteins specifically modified by phosphorylation on tyrosine. Indeed, after 30 min of stimulation with mAb46, we could observe a clear tyrosine phosphorylation of C3G ( Figure 4c ). Taken together, we conclude that activated mALK recruits C3G/CrkL and that this complex formation results in tyrosine phosphorylation of C3G.
C3G knockdown inhibits ALK-stimulated neurite outgrowth
To address a function of C3G in ALK-induced neurite outgrowth, we once more used RNAi to suppress endogenous C3G expression levels in PC12 cells. C3G protein levels were decreased to a similar extent in both mALK-expressing and mALK-nonexpressing PC12 cells ( tions in the neuroblastoma cell line IMR-32, made by Radha et al. (2008) . The molecular mechanisms behind the increase of C3G proteins are unclear and we have not investigated this further in this study. After NGF stimulation, neurite outgrowth in mALK-nonexpressing PC12 cells with suppressed C3G levels was reduced by approximately 30% as compared to control cells (Figures 5b and c) . This was confirmed with a second independent siRNA targeting C3G (Supplementary Figure 2) . Neurite outgrowth induced by mAb46-mediated mALK activation was reduced to a comparable degree in cells transfected with siC3G. Given that the decrease in neurite outgrowth after treatment with siC3G was not as pronounced as in Rap1 knockdown cells, we hypothesize that this may reflect other possible mechanisms of Rap1 activation and/or the incomplete knockdown of C3G. Further, to confirm a function for C3G in the activation of Rap1, we used Rap1 pulldown assays to investigate mALK-expressing PC12 cells that were transfected either with sicontrol or siC3G. Indeed, mALK-positive PC12 cells with downregulated C3G expression levels display reduced levels of GTP-bound Rap1 in comparison to control on stimulation (Figure 5d , compare lane 4 with 2). On the basis of these results, we conclude that C3G can be activated by mALK and indeed appears to have a function in mAb46-induced neurite outgrowth and the activation of Rap1 in PC12 cells.
To verify this further, we used YFP-or V5-tagged human C3G to analyze the effect of C3G overexpression on neurite outgrowth in mALK-expressing and mALKnonexpressing PC12 cells (Supplementary Figure 1) . Transfection of either YFP-or V5-tagged human C3G had no significant impact on basal neurite outgrowth Quantification of neurite outgrowth assays of mALK-negative and mALK-positive PCmALK cells transfected with either control siRNA or siRap1 together with pmaxGFP. Cells were stimulated with 100 ng/ml nerve growth factor (NGF) or 1 mg/ml mAb46, respectively. After 48 h 100 GFP-positive cells were analyzed and cells extending neurites with a length twice as long as the cell body were counted as neurite bearing cells. The experiment was carried out in triplicate. Each sample within an experiment was performed in duplicate.
Activation of the small GTPase Rap1 by ALK C Schönherr et al levels in either mALK-expressing or mALK-nonexpressing PC12 cells. However, whereas overexpression of C3G had no effect on neurite outgrowth in NGFstimulated mALK-nonexpressing PC12 cells, V5-tagged C3G could indeed trigger a mild but significant increase (23%) in neurite outgrowth in ALK-expressing PC12 The small inhibitor NVP-TAE684 inhibits the activation of ALK as well as Rap1
The ALK inhibitor, NVP-TAE684, has been shown to be an inhibitor of NPM-ALK-driven cell proliferation and blocks activation of downstream targets of NPM-ALK signaling, such as ERK (Galkin et al., 2007) . We have therefore used NVP-TAE684 to examine signaling downstream of mouse ALK in this study. We observed a clear abrogation of Rap1-GTP loading and phosphorylation of ERK on treatment of mouse ALK-expressing cells with 0.2 mM NVP-TAE684 before stimulation (Figure 6a , compare lane 8 with 5, 6 and 7). As shown previously, activation of mALK with mAb46 without inhibitor pretreatment results in a clear activation of Rap1 in GST-RalGDS pulldown assays (Figure 6a , lower panels, compare lane 6 with 5, and Figure 1) . Further, treatment with NVP-TAE684 reduced mALKdriven ERK phosphorylation (Figure 6a , top panels, compare lane 6 with 8). As control, we treated PC12 cells with NVP-TAE684 inhibitor before stimulation with NGF, which mediates phosphorylation of ERK and differentiation of PC12 cells (Gotoh et al., 1990; Traverse et al., 1992; Hallberg et al., 1998; Galkin et al., 2007) . As predicted, NVP-TAE684 does not inhibit TrkA receptor signaling in response to stimulation with NGF and a clear ERK activation was observed (Figure 6a , top panel, compare lanes 3 and 4 with 1 and 2).
Rap1 does not appear to be required for mALK activation of Erk
We have also examined the requirement of Rap1 for Erk phosphorylation in response to activation of ALK. 
Activation of the small GTPase Rap1 by ALK C Schönherr et al
Indeed, in our hands, we observe that both mALK and TrkA are able to stimulate phosphorylation of ERK in a sustained manner regardless of the presence or absence of Rap1 (Figures 6b and c , compare lanes 1-6 with 7-12). In a second approach to evaluate the importance of Rap1 activity for activation of ERK, ALK-expressing Activation of the small GTPase Rap1 by ALK C Schönherr et al Figure 6 Knockdown of Rap1 by small-interfering RNA (siRNA) does not affect ERK phosphorylation both in ALK-nonexpressing and ALK-expressing PCmALK cells. (a) Rap1 pull downs of cell lysates from mALK-expressing PCmALK cells. Cells were induced for ALK expression and serum starved for 24 h. Before stimulation with 1 mg/ml mAb46 for the indicated times, cells were treated with 0.2 mM NVP-TAE684 for 1 h. Cell lysates were precleared (see Materials and methods section), and incubated with GST-RalGDS beads. Bound proteins were subsequently analyzed by immunoblotting with anti-Rap1 antibodies. Rap1 in whole-cell lysates was used as loading control. Detection of phosphorylated ERK (p-ERK) was used as a control for mALK stimulation and inhibition of mALK by NVP-TAE684. (b) Effect of Rap1 knockdown by siRNA on ERK phosphorylation in mALK-nonexpressing PC12 cells and (c) mALK-expressing PCmALK cells. Cells were transfected with siRNAs against Rap1 (150 pmol) or control siRNA (150 pmol) with Amaxa Nucleofection Kit V. Starved ALK-nonexpressing PC12 cells were stimulated with 100 ng/ml nerve growth factor (NGF) (b) and starved ALK-expressing PC12 cells were stimulated with 1 mg/ml mAb46 (c) for the indicated times. Precleared cell lysates were subjected to immunoblot analysis for ERK phosphorylation (d). Overexpression of Rap1GAP was detected by HA antibodies. pan-ERK was monitored as loading control. The experiment was carried out in triplicate.
Activation of the small GTPase Rap1 by ALK C Schönherr et al PC12 cells were transfected with a plasmid encoding the Rap1-specific GAP, Rap1GAP (HA-Rap1GAP), which abrogates Rap1 activity and neurite outgrowth from these cells (Figure 3 ). Subsequent to transfection of mALK-expressing PC12 cells with HA-tagged Rap1GAP, ALK-induced ERK phosphorylation was monitored over time as indicated in Figure 6d . In agreement with our data using siRNA against Rap1 above, inhibition of Rap1 activity by Rap1GAP overexpression did not reduce the ability of activated mALK to mediate sustained phosphorylation of ERK (Figure 6d) . Thus, we conclude that Rap1 activity is not absolutely required for ERK activation; however, it is necessary for the neurite outgrowth responses of ALK-expressing PC12 cells.
Rap1 activity is required for efficient cell growth of neuroblastoma cell lines
Although the mALK-inducible PC12 cell line provides an excellent and controlled model for investigating signaling events downstream of ALK, the question of how significant the function of Rap1 is in ALK signaling under physiological conditions, remains. The recent discovery of activating ALK mutations in human neuroblastoma, together with reports implicating the C3G/Rap1 pathway in the survival of the human neuroblastoma cell line IMR-32 (Caren et al., 2008; Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008; Radha et al., 2008) , suggests that the involvement of the C3G/Rap1 pathway in the growth of neuroblastoma cell lines may occur in an ALK-dependent manner. To investigate this hypothesis, we used SK-N-SH and SH-SY5Y neuroblastoma cell lines, which carry an activating F1174L point mutation in the ALK receptor (Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008) . Using RNAi or HA-Rap1GAP to downregulate Rap1 activity, we analyzed Rap1-dependent cell growth of SK-N-SH and SH-SY5Y cells by monitoring the amount of viable cells over a period of 5 days (McDermott et al., 2008) . In both cell lines, reduction of endogenous Rap1 expression levels by siRNA resulted in a decrease of cell growth (Figures 7a-c) . In addition, reduction of Rap1 protein was able to block the stimulation of cell growth by mAb46, which can be observed in SH-SY5Y but not in SK-N-SH cells (Figures 7b and c) . Furthermore, we observed that the inhibition of Rap1 activity by Rap1GAP had the same effect on cell growth as depletion of Rap1 by RNAi (Figures 7a-c) . Therefore, we suggest that Rap1 not only is important for PC12 cell differentiation in response to ALK activation via C3G, but that it also has a significant function in regulating the growth of neuroblastoma cell lines.
Discussion
Our understanding of the signaling events elicited by the native ALK receptor has lagged behind studies of the oncogenic translocation-ALK fusion proteins (Palmer et al., 2009) . In mammalian systems, it has been shown that the full-length ALK RTK interacts with and mediates the activation of proximal signaling proteins, including Shc, FRS, PI3-kinase and PLCg, which in many cases leads to activation of ERK (Piccinini et al., 2002; Motegi et al., 2004; Degoutin et al., 2007) . Along with others, we have previously shown that activation of ALK triggers the differentiation of PC12 cells into sympathetic-like neurons, inducing a substantial neurite outgrowth Motegi et al., 2004; Gouzi et al., 2005; Moog-Lutz et al., 2005; Yang et al., 2007) . In Drosophila, ALK activates an ERK-dependent pathway leading to downstream transcription of molecules such as Duf/Kirre, Org, Hand and the TGF-b ligand Dpp Lee et al., 2003; Varshney and Palmer, 2006; Shirinian et al., 2007) , whereas in C. elegans ALK (SCD-2) has been suggested to modulate the TGF-b pathway (Reiner et al., 2008) .
In response to treatment with NGF, PC12 cells undergo differentiation from immature chromaffin cells into cells that resemble sympathetic neurons. This process is characterized by extension of neurites and development of electrical excitability (Greene and Kaplan, 1995) . The molecular mechanism behind the differentiation process in PC12 cells relies on the ability of NGF to induce sustained activation of the ERK MAPK family of serine/threonine kinases, which is mediated by Ras and Rap1 (Qiu and Green, 1991; Marshall, 1995; York et al., 1998) .
We show in this investigation that the stimulation of ALK, using agonist antibodies, results in activation of Rap1. Further, neurite outgrowth after ALK activation is reduced by transfecting cells with Rap1GAP or with two independent siRNAs against either Rap1 or its GEF C3G, suggesting a function for Rap1 activation in ALK-stimulated neurite outgrowth. Furthermore, we also observed a decrease in the ability of mALK to load Rap1 proteins with GTP when cells are transfected with two different siRNA against C3G and Rap1 or treated with a small selective ALK inhibitor, NVP-TAE684, on stimulation.
Although we clearly observe a function for Rap1 in the ALK-induced differentiation response, we have been unable to define a function for Rap1 in the activation of ERK by ALK. Our investigations show that the phosphorylation status of Erk on stimulation of mALK is unaffected by either the knockdown of C3G and Rap1 siRNA or by the transient overexpression of Rap1GAP (Figures 5 and 6 ). This would suggest that Rap1 activation is not a critical requirement in the activation of ERK by ALK in our system. In addition, we also observe a prolonged phosphorylation of ERK on stimulation with NGF when cells were treated with siRNA Rap1, which is in agreement with previous published results (Zwartkruis et al., 1998) .
Although activation of Rap1 and C3G appear to be essential for neurite outgrowth in ALK-expressing PC12 cells, our results imply another scenario leading to the prolonged ERK phosphorylation that does not invoke activation of Rap1 and C3G. The question of the molecular mechanisms underpinning the phosphorylation of Erk on stimulation of mouse ALK constitutes the basis for future investigations. Although not examined in this study, the FRS2 adaptor has been reported to be recruited by ALK after antibody-based ALK activation in PC12 cells (Degoutin et al., 2007) , suggesting that an ALK/FRS2/CrkL/C3G-complex may be assembled on activation of the ALK RTK. Previous reports indicate that overexpression of a constitutively active Rap1 mediates neurite outgrowth in PC12 cells (Vossler et al., 1997) , and it has been suggested that neurite outgrowth by NGF does not require sustained activation of Erk (York et al., 1998) . Here we show that sustained activation of Erk pathway is sufficient to propel the differentiation process. Rather, Rap1 and putative downstream target molecules of Rap1 are determinants for differentiation in PC12 cells stimulated with NGF and in stimulated ALK-expressing PC12 cells.
It is important to note that difficulties arise in comparing results of similar nature, such as PC12 cells and Rap1 activation, because the genetic composition and variation of different clones of PC12 cells varies.
Our results regarding C3G are in line with those of Hisata et al. (2007) and Radha et al. (2008) , who have also observed decreased neurite outgrowth on knockdown of endogenous Rap1 or C3G levels in PC12 cells. The molecular mechanism used appears to involve both CrkL and C3G, because stimulation of ALK results in formation of a multiprotein complex, containing CrkL and C3G, together with the activated ALK receptor. Indeed, activation of ALK also leads to tyrosine phosphorylation of C3G, which is in agreement with previous reports showing C3G activation in response to various exogenous stimuli (de Jong et al., 1998; Ichiba et al., 1999) . Rap1 is the first small GTPase that has been investigated downstream of mALK so far and it is clear that inhibition of mALK using the small ALK-inhibitor NVP-TAE684 abrogates the GTP-loading of Rap1, together with diminished ERK activation. A number of reports suggest that C3G has an inhibitory function in cell proliferation (Schmitt and Stork, 2002; Stork, 2003; Guerrero et al., 2004) . Indeed, activation of C3G by NGF or overexpression of C3G has been shown to mediate cell-cycle arrest in the neuroblastoma cell line IMR-32 (Radha et al., 2008) , reinforcing a function for Rap1 in this process.
Although it is clear that activation of ALK in PC12 cells triggers activation of the small GTPase Rap1 as well as neurite outgrowth, the significance of this pathway in tumor development is unclear. It has been shown that Rap1 is activated by cAMP, which can inhibit or enhance cell proliferation, depending on the cell type. It has been further proposed that both the inhibitory and enhancing effects of cAMP on cell proliferation are mediated by Rap1, which can act either antagonistically or synergistically with Ras, depending on the cellular context (Bos et al., 2001; Schmitt and Stork, 2001; Ribeiro-Neto et al., 2002) . Thus far, no Rap1-activating mutations have been identified in human tumors (Gyan et al., 2005; Zemojtel et al., 2006; Matsuse et al., 2009) . However, this does not exclude the possibility that Rap1 is a potential member in oncogenesis via alternative mechanisms, such as overexpression or downregulation of Rap1, or any of the regulatory proteins acting upstream and downstream of Rap1 (Altschuler and Ribeiro-Neto, 1998; Ishida et al., 2003; Yajnik et al., 2003; Tsygankova et al., 2007; Bailey et al., 2009) .
A function for ALK in cancer development is well established, and the recently reported ALK gain-offunction mutations observed in patients with neuroblastoma (Caren et al., 2008; Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008; Palmer et al., 2009) suggest that a connection between ALK and Rap1 may be of relevance in neuroblastomas. The IMR-32 neuroblastoma cell line in which C3G has been examined (Radha et al., 2008) is characterized as containing a wild-type ALK RTK. However, the growth of this cell line is inhibited by PF-2341066, a c-MET and ALK inhibitor, suggesting that ALK signaling contributes to IMR-32 cell growth at some level (Janoueix-Lerosey et al., 2008) . Furthermore, ALK-specific small-hairpin RNA treatment of IMR-32 cells leads to considerable inhibition of focus formation and growth arrest (Janoueix-Lerosey et al., 2008) . Examination of two additional neuroblastoma cell lines-SK-N-SH and SH-SY5Y-which contain the activating ALK point mutation F1174L, strengthens the potential importance of the C3G/Rap1 pathway for cell proliferation in neuroblastoma.
Interestingly, we were unable to observe an increase in cell proliferation of SK-N-SH cells on stimulation with anti-ALK agonist antibodies in conditions of normal serum levels. However, abrogation of the Rap1 signaling cascade either by siRNA or by overexpression of Rap1-GAP clearly reduced cell proliferation in both cell lines. Previous observations-before the identification of the ALK F1174L mutation in SK-N-SH cells-of cells cultured in reduced serum conditions suggest that stimulation of ALK with agonist antibodies promotes cell growth and neurite outgrowth in SK-N-SH cells, indicating a function for ALK in pathogenesis of neuroblastoma (Motegi et al., 2004) . In contrast to SK-N-SH cells, SH-SY5Y cells showed an increase in cell growth on stimulation with mAb46. In consideration of potential treatments for patients with neuroblastoma, such observations highlight the importance of understanding the genetic disposition of individual tumors, because both cell lines contain the same mutation within the kinase domain of ALK, but only SH-SY-5Y cells can be further stimulated on ALK activation. Although intriguing, the mechanisms behind this discrepancy are unknown and have not been investigated here. What is clear is that in both cell lines, abrogation of the ALK-Rap1 connection reduced the cell proliferation rate dramatically.
Taken together, the results presented here show that ALK activation leads to formation of a complex between the receptor and the CrkL/C3G protein complex, in which C3G becomes tyrosine phosphorylated in response to ALK stimulation. This activated complex activates Rap1, leading to neurite outgrowth in PC12 cells. Further, we show that Rap1 has an important function in the proliferation of tumorigenic neuroblastoma cells. Currently, there are no clinically approved treatments for oncogenic malignancies caused by inappropriate ALK activation that directly target ALK or downstream ALK-driven signaling. However, disruption of the ALK/Rap1 pathway may prove worthy of further investigation.
Materials and methods
Antibodies
Mouse anti-Rap1 (1:1000) and mouse anti-pan-ERK (1:5000) were purchased from BD Transduction Laboratories, Franklin Lakes, NJ, USA; rabbit anti-pERK (1:1000) from Cell Signaling Technology, Danvers, MA, USA; and rabbit anti-C3G (H-300 and C-19) (1:1000), rabbit anti-CrkL (C-20) (1:1000) in addition to mouse anti-phosphotyrosine pY99 (1:1000) from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Anti-phosphotyrosine 4G10 agarose conjugate was obtained from Upstate, Lake Placid, NY, USA . The activating monoclonal antibody mAb46 and the chicken anti-mALK antibody have been described previously Yang et al., 2007) . The horseradish peroxidase-coupled secondary antibodies goat anti-rabbit IgG and goat anti-mouse IgG were from Thermo Scientific, Waltham, Activation of the small GTPase Rap1 by ALK C Schönherr et al MA, USA and rabbit anti-chicken IgY from Pierce, Rockford, IL, USA (1:5000).
Plasmids pMT2-HA-Rap1GAP, pcDNA3.1-YFP-humanC3G and pcDNA3.1-V5-humanC3G were generous gifts from JL Bos (Utrecht University, Utrecht, the Netherlands). For transfection control pmaxGFP from Amaxa Biosystems (Cologne, Germany) was used. For the GTP-Rap1 pull-down assay, GST-RalGDS proteins were used (Franke et al., 1997) . For the cell growth assay, cells were transfected with pcDNA3 as control.
The pTRE-Tight-puromycin (pTTP) plasmid was generated from pTRE-Tight (BD Biosciences, San Jose, CA, USA, Cat. No. 631059). The XhoI site at position 602 (two XhoI sites are present in pTRE-Tight) was eliminated with a fill-in reaction. Thereafter the modified TRE-Tight was opened with PvuI/XhoI (position 1985/2), and this fragment was replaced with a PvuI/XhoI (position 3143/2) fragment from pTRE2pur (BD Biosciences, Cat. No. 6254-1). A generated PCR NotI mALK fragment (position 428 to 5767) from pME-mALK (kind gift from Dr Tadashi Yamamoto, Tokyo, Japan) was inserted at the NotI site in the pTTP vector (creating pTTPmALK) using standard plasmid manipulation procedures and sequenced before used.
Cell culture
The stable PC12 Tet-on clone PCmALK was generated by transfecting (Lipofectamine; Invitrogen, Paisley, GB) PC12 Tet-on cells with the pTTPmALK plasmid according to manual (BD Biosciences, Cat. No. 630921) . Stable clones were selected in Dulbecco's modified Eagle's medium, containing 10% horse serum (MP Biomedicals, Solon, OH, USA), 5% tetracycline-screened fetal calf serum (HyClone, Logan, UT, USA), penicillin, streptomycin, L-glutamine, 100 mg/ml G418 and 2 mg/ml puromycin at 37 1C and 5% CO 2 . The cell clones were screened for mALK expression by induction with 1 mg/ml doxycycline for 24 h before analysis by immunoblotting. Neuroblastoma cell lines SK-N-SH and SH-SY5Y were cultured in Dulbecco's modified Eagle's medium, containing 10% fetal calf serum, penicillin, streptomycin and L-glutamine. Cell lysis, immunoprecipitation and immunoblotting were preformed as described (Yang et al., 2007) .
RNA interference
For Rap1 and C3G knockdown, double-stranded 25-nucleotide RNA duplexes (Stealth RNA-mediated interference; Invitrogen) targeting Rap1 (using siRNA-Rap1 no. 2 in Figures 2b, 6b and c and 7a and b and siRNA no. 3 in Supplementary Figure 2 , which does not recognize Rap1B) or C3G (using siRNA-C3G no. 1 in Figure 5 and siRNA-C3G no. 2 in Supplementary Figure 2) were transfected into PCmALK cells using cell line nucleofector kit V (Amaxa Biosystems) with an efficiency of 60-80%. As a negative control Stealth RNAi negative control medium CG duplex (Invitrogen) was used.
Pull-down assay for GTP-Rap1 PC12 cells expressing mALK were starved for 24 h and when indicated treated with 0.2 mM of the ALK inhibitor NVP-TAE684 for 1 h before stimulation with 1 mg/ml mAb46 for the indicated times Yang et al., 2007) . Whole-cell lysates were harvested and analyzed as described (Ren et al., 1999; Henriksson et al., 2002) .
Cell transfection and neurite outgrowth assay PCmALK cells were transfected using cell line nucleofector kit V (Amaxa Biosystems) according to manufacturer's protocol with an efficiency of 60-80%. For the neurite outgrowth assay, cells were transfected with 0.5 mg pmaxGFP and 2.5 mg DNA and 150 pmol siRNA, respectively. Cells were stimulated with 100 ng/ml NGF 2.5S (Grade I) (Alomone Labs, Jerusalem, Israel) or 1 mg/ml mAb46. Quantification of neurite outgrowth in the transfected PCmALK cells was carried out as described . Experiments were performed in triplicates, and each sample within an experiment was performed in duplicate.
Cell growth assay For cell growth determination, 1 Â 10 4 SK-N-SH and SH-SY5Y cells per well were seeded in 24-well plates. Transfection was performed with Lipofectamine 2000 (Invitrogen) according to manufacturer's protocol with an efficiency of 60-80%. As control, cells were transfected with 0.4 mg pcDNA3. For knockdown of Rap1, cells were transfected with 20 pmol siRap1. Rap1 activity was inhibited by transfection with 0.4 mg HA-Rap1GAP. The next day cells were stimulated with 1 mg/ ml mAb46. The amount of viable cells was determined by Trypan blue staining for 5 days. Each sample was performed in triplicate.
